Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Price:
78.15
EUR
-1.14%
Market Closed
Market Cap:
€4B
Relative Value
The Relative Value of one
ROVI
stock under the Base Case scenario is
50.14
EUR.
Compared to the current market price of 78.15 EUR,
Laboratorios Farmaceuticos ROVI SA
is
Overvalued by 36%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ROVI
Relative Value
Base Case
50.14
EUR
Overvaluation 36%
Multiples Across Competitors
ROVI Competitors Multiples
Laboratorios Farmaceuticos ROVI SA Competitors
Laboratorios Farmaceuticos ROVI SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
4B EUR | 5.5 | 33 | 21.3 | 25.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD | 14.7 | 46.5 | 31.3 | 33.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF | 4.8 | 31.1 | 13.1 | 15.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP | 5.5 | 31.6 | 17.4 | 24.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF | 5.5 | 22.2 | 13.7 | 17.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD | 4.7 | 16.7 | 10.4 | 12.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK | 4.3 | 13 | 9.5 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD | 2.4 | 19.5 | 7.3 | 9.7 | |
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR | 2.8 | 15.8 | 8 | 11.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
